## FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

Check this box if no longer subject t Section 16. Form 4 or Form 5	0.
obligations may continue. See Instruction 1(b).	

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
lame and Address of Reporting F

defense	d to satisfy the e conditions of ee Instruction 1	Rule 10b5-																	
Name and Address of Reporting Person*     Skorpios Trust					2. Issuer Name and Ticker or Trading Symbol Stoke Therapeutics, Inc. [ STOK ]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director						
(Last) (First) (Middle) 195 ARCH. MAKARIOS III AVE.					3. Date of Earliest Transaction (Month/Day/Year) 09/19/2024								- Officer (give title Other (specify below) below)						
NEOCLEOUS HOUSE				4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)						
(Street) LIMASSOL G4 3030												Form filed by One Reporting Person  Form filed by More than One Reporting Person							
(City)	(St	ate) (Z	Zip)																
		Table	I - N	lon-Deriva	tive	Secu	rities	Ac	quire	d, Di	sposed of	, or B	enefic	ial	ly Own	ed			
1. Title of Security (Instr. 3)  2. Transactio Date (Month/Day/Y				med on Dat Day/Ye				Disposed Of (	Acquired (A) or (D) (Instr. 3, 4 a		nd Securit Benefic Owned		s ally following	Form:	nership : Direct · Indirect str. 4)	7. Nature of Indirect Beneficial Ownership			
									Code	v	Amount	(A) or (D)	Price		Reported Transact (Instr. 3 a	ion(s)			(Instr. 4)
Common Stock 09/19/202				24				S		1,937,500	D	\$14.	05	8,900	6,181		I	See Footnote <sup>(</sup>	
		Tal	ole II								posed of, convertib				Owne	d			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Date Execution			Transaction Code (Instr.		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		te Exe ration I th/Day		7. Title and Amount of Securities Underlying Derivative Security (Ins 3 and 4)		S (I	. Price of Perivative Security Instr. 5)	9. Number derivative Securitie Beneficia Owned Following Reported Transact (Instr. 4)	e es ally g	10. Ownersh Form: Direct (D or Indire (I) (Instr.	Benefic Owners ct (Instr. 4
					Code	v	(A)	(D)	Date Exerc	cisable	Expiration Date	Title	Amount or Number of Shares						
	nd Address of	Reporting Person*									,							,	*

1. Name and Address <u>Skorpios Trust</u>	of Reporting Person*						
(Last)	(First)	(Middle)					
195 ARCH. MAK	ARIOS III AVE.						
NEOCLEOUS HOUSE							
(Street)							
LIMASSOL	G4	3030					
(City)	(State)	(Zip)					
1. Name and Address Blue Horizon E	. •						
(Last)	(First)	(Middle)					
195 ARCH. MAK	ARIOS III AVE.						
NEOCLEOUS HO	OUSE						
(Street)							
LIMASSOL	G4	3030					
(City)	(State)	(Zip)					
Name and Address of Reporting Person*							

Ezbon Interna	ational Ltd					
(Last)	(First)	(Middle)				
195 ARCH. MA	KARIOS III AVE.					
NEOCLEOUS H	IOUSE					
(Street)						
LIMASSOL	G4	3030				
(City)	(State)	(Zip)				
1. Name and Address  Montrago Tru	es of Reporting Person* ustees Ltd					
(Last)	(First)	(Middle)				
195 ARCH. MA	KARIOS III AVE					
NEOCLEOUS HOUSE						
(Street)						
LIMASSOL	G4	3030				
(City)	(State)	(Zip)				

## Explanation of Responses:

1. Blue Horizon Enterprise Ltd. ("Blue Horizon") is the direct owner of 4,967,621 shares of the issuer's common stock and Ezbon International Limited ("Ezbon") is the direct owner of 3,938,560 shares of the issuer's common stock. Skorpios Trust ("Skorpios") is the sole owner of each of Blue Horizon and Ezbon. Montrago Trustees Limited ("Montrago Trustees") is the corporate trustee of Skorpios Trust. Each of Blue Horizon and Ezbon disclaim beneficial ownership of the shares of the issuer's common stock held by the other, and each of Skorpios Trust and Montrago Trustees disclaim beneficial ownership of the issuer's securities except to the extent of their pecuniary interest therein.

/s/ Androulla Papadopoulou, Authorized Signatory on behalf of Skorpios Trust	09/23/2024
/s/ Eleni Constantinou Kyriacou, Authorized Signatory on behalf of Blue Horizon Enterprises Ltd.	09/23/2024
/s/ Eleni Constantinou Kyriacou, Authorized Signatory on behalf of Ezbon International Limited	09/23/2024
/s/ Androulla Papadopoulou, Authorized Signatory on behalf of Montrago Trustees Limited	09/23/2024
** Signature of Reporting Person	Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

 $<sup>^{\</sup>star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

<sup>\*\*</sup> Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).